Webinar Program Description
Specifically designed for attendees who are unable to attend an Advances in Cancer Immunotherapy™ (ACI) program in person, the Advances in Cancer Immunotherapy™ Webinar offers attendees the opportunity to participate in the program online. Webinar attendees receive the educational benefits of attending an ACI program, including the ability to participate in Audience Response System (ARS) questions during the program and ask questions of program faculty during Q&A sessions.
After registering for the webinar, webinar attendees will receive additional instructions via email with a link to the webinar and a webinar access code.
Share this event in your network
Organizers:
Christian Capitini, MD – University of Wisconsin Carbone Cancer Center
Sigrun Hallmeyer, MD – Advocate Medical Group
Anne Wolvin, RN – University of Wisconsin Carbone Cancer Center
Program Purpose
Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE- and CNE-certified programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these six-hour programs will facilitate understanding of:
- The rationale for common approaches to immunotherapy
- The clinical applications of immunotherapy for disease states with FDA-approved treatments (melanoma, and lung, genitourinary, hematologic, and head and neck cancers)
- Operational and reimbursement barriers to implementing immunotherapy in a community setting and strategies to overcome them
- The identification and management of immune-related adverse events from the nursing and prescriber perspective in the clinic and emergency settings
Webinar attendees will also have an opportunity for connecting with regional experts in the immunotherapy field through two Immuno-Oncology (IO) Cup o' Joe webinars after the program and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.
For more information, including program objectives, click here.
This program is presented in collaboration with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC).
Program Registration
SITC members are eligible for discounted registration rates. To receive discounted member rates, your membership dues must be current through 2017.
Click here to learn more about the registration rates for members and non-members for this program.
Program Agenda
Preprogram Course: Introduction to Immunology
Participation in this online preprogram course is strongly recommended as it contains information that will not be covered at the onlin program on August 12. This interactive course provides foundational knowledge that is necessary for understanding cancer immunotherapy content that will be discussed at the in-person program. Please click HERE to access the course.
August 12 Program
Presentations include time for Audience Response System (ARS)-assisted audience
interaction as well as general question and answer time.
7 – 8 a.m.
|
Check-in, Onsite Registration and Networking
|
Part A: Introduction to Incorporating Immunotherapy Into Clinical Practice
|
Session I: From Basic Principles to Clinical Applications of Cancer Immunotherapy
|
8 – 8:05 a.m.
|
Welcome, Introduction, and Pretest Questions by the Society for Immunotherapy of Cancer
|
8:05 – 8:35 a.m.
|
Basic Principles of Cancer Immunotherapy Monica Thakar, MD – Medical College of Wisconsin
|
8:35 – 8:55 a.m.
|
Immunotherapy for the Treatment of Melanoma Mark R. Albertini, MD – University of Wisconsin Carbone Cancer Center
|
8:55 – 9:15 a.m.
|
Immunotherapy for the Treatment of Lung Cancer Ticiana A. Leal, MD – University of Wisconsin Carbone Cancer Center
|
9:15 – 9:35 a.m.
|
Immunotherapy for the Treatment of Genitourinary Cancers Douglas G. McNeel, MD, PhD – University of Wisconsin Carbone Cancer Center
|
9:35 – 9:55 a.m
|
Immunotherapy for the Treatment of Hematologic Malignancies Timothy S. Fenske, MD – Medical College of Wisconsin
|
9:55 – 10:15 a.m
|
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD – Aurora Health Care
|
10:15 – 10:25 a.m
|
Break
|
Session II: Overcoming Barriers to Incorporating Immunotherapy Into Community Practice
|
10:25 – 10:30 a.m.
|
Information About the Society for Immunotherapy of Cancer Resources
|
10:30 – 11 a.m.
|
Effective Practices for Incorporating Immunotherapy Into Hospital Operations Sigrun Hallmeyer, MD – Advocate Medical Group
|
11 – 11:30 a.m.
|
Coverage and Reimbursement Challenges and Strategies Sigrun Hallmeyer, MD – Advocate Medical Group
|
11:30 – 11:35 a.m.
|
Take-Home Points for Part A
|
11:35 a.m. – noon
|
Lunch
|
Part B: Immune-Related Adverse Event (irAE) Management
|
noon – 12:20 p.m.
|
Mechanisms of Immune-Related Adverse Events Bryon D. Johnson, PhD – Medical College of Wisconsin
|
12:20 – 12:50 p.m.
|
Nursing Perspective on irAEs: Patient Education, Monitoring and Management Anne Wolvin, RN – University of Wisconsin Carbone Cancer Center
|
12:50 – 1:20 p.m.
|
Management and Mitigation of irAEs for Immunotherapy Prescribers Christian Capitini, MD – University of Wisconsin Carbone Cancer Center
|
1:20 – 1:50 p.m.
|
Identification and Management of Immune-Related Adverse Events in the Emergency Setting Ronny Mario Otero MD, FAAEM - University of Michigan
|
1:50 – 1:55 p.m.
|
Posttest Questions by the Society for Immunotherapy of Cancer
|
1:55 – 2 p.m.
|
Take-Home Points for Part B and Closing Remarks
|
The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants
from Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc. and Prometheus Laboratories Inc.